IVF Industry Trade Group Uses Advocacy Non-Profit to Push Money-Making Agenda
By Editor,
ReproTech Truths
| 04. 10. 2019
In the last few years, ASRM has aggressively courted RESOLVE, once a purely grassroots group of women helping women get support for infertility. RESOLVE’s grassroots nationwide membership was its crown jewel.
Eager to gain access to RESOLVE’s membership, Big Pharma, along with ASRM, have each made large cash infusions in the form of sponsorships and events.

Industry Mouth Piece
RESOLVE has since become a lobbying group for the industry. Its well-compensated executive team gets paid by Coulter Companies, now MCI USA according to RESOLVE’s latest tax filings. The industry-funded team works alongside its corporate council, donors and advocates — a who’s who of IVF clinic owners and service providers — to mobilize consumers to do its bidding: lobby to get insurance companies to compensate the industry for dispensing IVF cycles. It opens up a large untapped revenue stream.
RESOLVE today announced its full embrace of ASRM with an email blast that reads in part:
“ASRM has committed to a three-year investment in RESOLVE’s Access to Care programs, which will allow for new staff resources to grow these important programs...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...